Alyeska Investment Group
AIMT

Alyeska Investment Group’s Aimmune Therapeutics AIMT Stock Holding History

Alyeska Investment Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-173,591
Closed -$4.67M – 556
2018
Q2 		$4.67M Buy
173,591
+53,962
+45% +$1.65M 0.04% 278
2018
Q1 		$3.81M Buy
+119,629
New +$4.21M 0.03% 309
2015
Q4 		– Sell
-50,000
Closed -$1.27M – 502
2015
Q3 		$1.27M Buy
+50,000
New +$1.17M 0.01% 368

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alyeska Investment Group's AIMT Position: Q3 2018 in Review

Alyeska Investment Group sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 173,591 shares — an estimated $4.67M sold.

Alyeska Investment Group first reported a position in AIMT in Q3 2015 and held it in 3 quarters. The position peaked at $4.67M in Q2 2018. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Alyeska Investment Group reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 173,591 Aimmune Therapeutics shares in Q3 2018, an estimated $4.67M.
  • Alyeska Investment Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 3 quarters.
  • Alyeska Investment Group's Aimmune Therapeutics position peaked at $4.67M in Q2 2018.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.